- Conditions
- Device Latency
- Interventions
- MIND1 System
- Device
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Walnut Creek, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Interventions
- Aripiprazole + IEM (Ingestible Event Marker)
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 4
- States / cities
- Granada Hills, California • Rochester, New York • Durham, North Carolina + 1 more
- Conditions
- Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Interventions
- Placebo IEM tablet, Abilify MyCite®, D-Tect Patch
- Drug · Device
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Garden Grove, California
- Conditions
- Device Latency
- Interventions
- Placebo, Combination product of Aripiprazole + IEM + Sensor + MIND1 Application
- Drug · Combination Product
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Walnut Creek, California
- Conditions
- Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Diseases
- Interventions
- Aripiprazole, Ingestible Event Marker (IEM)
- Drug · Device
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 12
- States / cities
- Cerritos, California • Garden Grove, California • Long Beach, California + 9 more
- Conditions
- Schizophrenia, Mental Disorder, Nervous System Diseases
- Interventions
- MIND1 System
- Device
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 6
- States / cities
- Cerritos, California • Garden Grove, California • Oceanside, California + 3 more